Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W D Figg

Showing results (121-130 of 135) with videos related to

Pageof 14
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2001
A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interactionE C Kohn, E Reed, G A Sarosy, et al.
Clinical Pharmacology and Therapeutics|September 20, 2012
OATP1B1 polymorphism as a determinant of erythromycin dispositionC S Lancaster, G H Bruun, C J Peer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2001
Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasmsE A Sausville, S G Arbuck, R Messmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemiaS D Gore, L J Weng, S Zhai, et al.
Cancer Research|August 12, 1998
Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoproteinE Fuse, H Tanii, N Kurata, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2000
A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphomaR A Messmann, E S Vitetta, D Headlee, et al.
Breast Cancer Research and Treatment|September 14, 2016
ANG1005 for breast cancer brain metastases: correlation between <sup>18</sup>F-FLT-PET after first cycle and MRI in response assessmentC C O'Sullivan, M Lindenberg, C Bryla, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2001
A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancerW D Figg, W Dahut, P Duray, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998
Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcomaL Welles, M W Saville, J Lietzau, et al.
Blood|August 15, 1996
A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphomaM J Stone, E A Sausville, J W Fay, et al.
Pageof 14

Showing results (121-130 of 135) with videos related to

Sort By:
Pageof 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2001
A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interactionE C Kohn, E Reed, G A Sarosy, et al.
Clinical Pharmacology and Therapeutics|September 20, 2012
OATP1B1 polymorphism as a determinant of erythromycin dispositionC S Lancaster, G H Bruun, C J Peer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2001
Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasmsE A Sausville, S G Arbuck, R Messmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemiaS D Gore, L J Weng, S Zhai, et al.
Cancer Research|August 12, 1998
Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoproteinE Fuse, H Tanii, N Kurata, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2000
A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphomaR A Messmann, E S Vitetta, D Headlee, et al.
Breast Cancer Research and Treatment|September 14, 2016
ANG1005 for breast cancer brain metastases: correlation between <sup>18</sup>F-FLT-PET after first cycle and MRI in response assessmentC C O'Sullivan, M Lindenberg, C Bryla, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2001
A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancerW D Figg, W Dahut, P Duray, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998
Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcomaL Welles, M W Saville, J Lietzau, et al.
Blood|August 15, 1996
A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphomaM J Stone, E A Sausville, J W Fay, et al.
Pageof 14